Record Display for the EPA National Library Catalog


Main Title Evaluation of the potential carcinogenicity of lead and lead compounds : in support of reportable quantity adjustments pursuant to CERCLA section 102.
CORP Author Environmental Protection Agency, Washington, DC. Office of Health and Environmental Assessment.
Publisher U.S. Environmental Protection Agency, Office of Research and Development, Office of Health and Environmental Assessment,
Year Published 1989
Report Number EPA/600/8-89/045A
Stock Number PB89-181366
OCLC Number 19645868
Subjects Lead--Toxicology ; Environmental health
Additional Subjects Lead(Metal) ; Carcinogens ; Environmental surveys ; Antineoplastic agents ; Exposure ; Laboratory animals ; Toxicology ; Plumbers ; Chemical industry ; Electric batteries ; Public health ; Epidemiology ; Industrial hygiene ; Smelters ; Lead compounds ; Risk assessment ; Occupational safety and health ; Pharmacokinetics
Internet Access
Description Access URL
Library Call Number Additional Info Location Last
EHAM  RC268.7.L3EPA-600 8-89-045 Region 1 Library/Boston,MA 04/29/2016
EJED  EPA 600/8-89-045A OCSPP Chemical Library/Washington,DC 07/28/1989
EKBD  EPA/600/8-89/045A Research Triangle Park Library/RTP, NC 05/19/1989
ELBD ARCHIVE EPA 600-8-89-045a Received from HQ AWBERC Library/Cincinnati,OH 10/04/2023 DISPERSAL
ERAD  EPA 600/8-89-045a 2 copies Region 9 Library/San Francisco,CA 03/25/2016
ESAD  EPA 600-8-89-045A Region 10 Library/Seattle,WA 03/23/2010
NTIS  PB89-181366 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation xi, 128 pages : illustrations ; 28 cm
Information on the potential carcinogenicity of lead and lead compounds is summarized and evaluated. The human studies provide suggestive evidence of carcinogenicity, but, because of confounding exposures to other carcinogens and the lack of measurements of lead exposure, are inadequate to prove or disprove carcinogenicity. Numerous long-term animal studies, using several different forms of lead and routes of exposure, provide sufficient evidence. This combination of evidence, together with information from short-term tests, other toxic effects, and pharmacokinetic properties, yields a classification of lead and lead compounds as probably human carcinogen, Group B2. No specific cancer potency has been estimated for lead. Many factors influence lead-induced cancer, creating difficulties in selecting an appropriate measure of dose. Cross-species pharmacokinetic models are needed before the animal studies can be used to estimate a human cancer potency. Because it has been relatively high concentrations of lead that have increased the incidence of cancer in animals, it seems appropriate to characterize the cancer potency of lead as low, placing lead in potency Group 3.
"EPA/600/8-89/045A." "External Review Draft." "March 1989."